James Kochenderfer, MD
Enriched profileSenior Investigator, Surgery Branch · National Cancer Institute Surgery Branch
James Kochenderfer is Senior Investigator, Surgery Branch at National Cancer Institute Surgery Branch. OpenAlex indexes 246 publications with 27,340 citations (h-index 56); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 31 Aug 2026
James Kochenderfer, MD, is Senior Investigator, Surgery Branch at National Cancer Institute Surgery Branch, Center for Cancer Research, NIH. The public record shows 246 publications with 27,340 citations (h-index 56), centered on CAR-T cell therapy research, Viral Infectious Diseases and Gene Expression in Insects, Virus-based gene therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 1 companies.
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: CAR-T cell therapy research
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 132.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Sponsor: National Cancer Institute (NCI)
- Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Sponsor: National Cancer Institute (NCI)
- Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 31 Aug 2026
1 company reported payments to CMS in program years 2022–2022. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20221 payment
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 31 Aug 2026
28 congress contributions (2012–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM
ASH Annual Meeting
ASH2025Co-author - In Vivo clonal dynamics of alloreactive CAR T cells reveal mechanisms limiting gvhd risk following allogeneic CAR T cell therapy
ASH Annual Meeting
ASH2025Co-author - Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 31 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.
Journal for immunotherapy of cancer
Article2026 - Chimeric antigen receptor T cell therapy for autoimmune disease.
Nature reviews. Immunology
Review2024 - Current understanding and management of CAR T cell-associated toxicities.
Nature reviews. Clinical oncology
Review2024 - Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Blood advances
Clinical Trial2024 - Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Nature medicine
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)Network
Updated 31 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 31 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/James-N-Kochenderfer-16142205
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/NCI_CCR_SB
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- Internal Medicine residency
Vanderbilt University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗ - Oncology fellowship
University of Texas M.D. Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗ - Hematology fellowship
Baylor College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
Awards & honors
honors on the public record- Clinical Research Forum 2020 Top 10 Clinical Research Achievement Award
for development of CAR T-cell therapy for myeloma
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fnih.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
Media & interviews
press, podcasts and appearances- "The status of anti-BCMA CAR T-cell therapy in multiple myeloma"
interview with Dr James Kochenderfer, Multiple Myeloma Hub
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →multiplemyelomahub.com ↗ - "James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma"
profile feature, ASH Clinical News
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic